Morphological evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer is gaining momentum as evidence strengthens the clinical relevance of this immunological biomarker. TILs in the post-neoadjuvant residual disease setting are acquiring increasing importance as a stratifying marker in clinical trials, considering the raising interest on immunotherapeutic strategies after neoadjuvant chemotherapy. TILs in ductal carcinoma in situ, with or without invasive carcinoma, represent an emerging area of clinical breast cancer research. The aim of this report is to update pathologists, clinicians and researchers on TIL assessment in both the post-neoadjuvant residual disease and the ductal carcinoma in situ settings. The International Immuno-Oncology Working Group proposes a method for assessing TILs in these settings, based on the previously published International Guidelines on TIL Assessment in Breast Cancer. In this regard, these recommendations represent a consensus guidance for pathologists, aimed to achieve the highest possible consistency among future studies.

Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ : a report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer / M.V. Dieci, N. Radosevic-Robin, S. Fineberg, G. van den Eynden, N. Ternes, F. Penault-Llorca, G. Pruneri, T.M. D'Alfonso, S. Demaria, C. Castaneda, J. Sanchez, S. Badve, S. Michiels, V. Bossuyt, F. Rojo, B. Singh, T. Nielsen, G. Viale, S. Kim, S. Hewitt, S. Wienert, S. Loibl, D. Rimm, F. Symmans, C. Denkert, S. Adams, S. Loi, R. Salgado. - In: SEMINARS IN CANCER BIOLOGY. - ISSN 1044-579X. - 52:Pt 2(2018), pp. 16-25.

Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ : a report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer

G. Pruneri;G. Viale;
2018

Abstract

Morphological evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer is gaining momentum as evidence strengthens the clinical relevance of this immunological biomarker. TILs in the post-neoadjuvant residual disease setting are acquiring increasing importance as a stratifying marker in clinical trials, considering the raising interest on immunotherapeutic strategies after neoadjuvant chemotherapy. TILs in ductal carcinoma in situ, with or without invasive carcinoma, represent an emerging area of clinical breast cancer research. The aim of this report is to update pathologists, clinicians and researchers on TIL assessment in both the post-neoadjuvant residual disease and the ductal carcinoma in situ settings. The International Immuno-Oncology Working Group proposes a method for assessing TILs in these settings, based on the previously published International Guidelines on TIL Assessment in Breast Cancer. In this regard, these recommendations represent a consensus guidance for pathologists, aimed to achieve the highest possible consistency among future studies.
Breast cancer; Ductal carcinoma in situ; Neoadjuvant; Residual cancer burden; Residual disease; Tumor-infiltrating lymphocytes; Cancer Research
Settore MED/08 - Anatomia Patologica
Article (author)
File in questo prodotto:
File Dimensione Formato  
Dieci_TILs.pdf

accesso aperto

Tipologia: Publisher's version/PDF
Dimensione 697.23 kB
Formato Adobe PDF
697.23 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2434/590504
Citazioni
  • ???jsp.display-item.citation.pmc??? 122
  • Scopus 217
  • ???jsp.display-item.citation.isi??? 207
social impact